Zilbrysq was found safe and effective in a clinical trial for generalized myasthenia gravis patients who switched from other C5 inhibitors.| Myasthenia Gravis News
The FDA has approved once-daily zilucoplan as Zilbrysq for adults with generalized MG who are positive for antibodies targeting AChR.| Myasthenia Gravis News
Study data show long-term treatment with Zilbrysq led to sustained reductions in disease severity in generalized myasthenia gravis patients.| Myasthenia Gravis News